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Background: Dengue infection is an endemic infectious disease and it can lead to
dengue fever, dengue hemorrhagic fever, and/or dengue shock syndromes. Dengue
NS2B/NS3 protease complex is essential for viral replication and is a primary target
for anti-dengue drug development. In this study, a NS2B/NS3 protease inhibition
assay was developed using AlphaScreen beads and was used to screen
compounds for their protease inhibition activities.
Methods: The assay system utilized a known NS2B/NS3 peptide substrate, a
recombinant of NS2B/NS3 protease with proprietary StrepTactin donor and
nickel chelate acceptor beads in 384-well format..e01023
lished by Elsevier Ltd. This is an open access article under the CC BY license
y/4.0/).
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demonstrated to be potentially useful with reasonable zʹ factor, coeﬃcient
variance and signal to background ratio. However, screening of synthesized
thioguanine derivatives using the optimized AlphaScreen assay revealed weak
NS2B/NS3 inhibition activities.
Conclusion: The AlphaScreen assay to screen for NS2B/NS3 protease inhibitors
is potentially applicable for high throughput screening.
Keywords: Bioinformatics, Biotechnology
1. Introduction
Dengue infection is an endemic infectious disease found mainly in tropical and sub-
tropical regions. According to the World Health Organization (WHO), nearly
50e100 million dengue infection cases occur every year. An estimated half a million
people with severe dengue infection require hospitalization each year, a large pro-
portion of whom are children and about 2.5% of those aﬀected with dengue, suc-
cumbed to this infection [1]. Dengue fever is caused by a vector-borne virus
transmitted by Aedes aegypti mosquitoes. Dengue virus (DENV) is a member of
the ﬂavivirus genus within the family of Flaviviridae [2, 3]. DENV possesses
four distinct serotypes that are closely related, however infection with one serotype
does not provide complete protection against the other three serotypes [2]. Second-
ary infection with a heterologous serotype is a risk factor for developing dengue
hemorrhagic fever or dengue shock syndrome [4].
DENV is categorized as an enveloped virus containing a 10.7kb single-stranded
RNA genome of positive strand polarity [5, 6, 7]. The RNA genome is transcribed
into a single polyprotein containing 3 structural proteins [envelope (E), pre-
membrane (prM) and capsid (C)] and 7 non-structural proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B and NS5) [8, 9, 10]. Co- and post-translational cleavage
are aided by a variety of host and viral proteases resulting in distinct structural pro-
teins [7]. Proteolytic processing in the region of the structural proteins is mediated by
a host cell signal peptidase that is located within the endoplasmic reticulum [11].
Cleavages at the NS2A/NS2B, NS2B/NS3, NS3/NS4A, and NS4B/NS5 sites are
catalyzed by the virus encoded two-component protease NS2B/NS3. This protease
also cleaves C/prM and various internal sites in C, NS2A, NS3 and NS4A [12]. The
cleavage activity of NS3 is aided by NS2B protein as a cofactor [13]. The NS2B/
NS3 protease complex is essential for viral replication and is a primary target for
the development of anti-dengue drugs [9, 14, 15].
The active site of the NS3 serine protease carries the catalytic triad, comprising of
three amino acid residues, namely H51, D75 and S135. The NS2B act as a cofactoron.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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between H51 and D75, allows H51 to deprotonate serine causing S135 to play a role
in fragmenting substrate [16]. In addition to the catalytic triad, the active site of NS3
also contained 4 sub-pockets, namely sub-pocket 1 (D129, S135, Y150, Y161), sub-
pocket 2 (D75, D82, G83, N84, N152), sub-pocket 3 (F85, Q86, L87) and sub-
pocket 4 (V154). Interactions with sub-pocket residues alongside with catalytic triad
aid in the binding aﬃnity and contribute to the inhibitory characteristics of the com-
pounds [6, 17, 18].
Currently, various eﬀorts are underway to ﬁnd strategies to manage this infectious
disease, and this includes screening for new chemical entities targeted against struc-
tural and/or nonstructural proteins involved in the viral replication and the develop-
ment of dengue vaccine. The ﬁrst licensed dengue vaccine, Dengvaxia has been
evaluated in 2 parallel Phase 3 randomized clinical trials, in Asia and Latin America.
However, vaccine eﬃcacy ranged from 31.3% to 79%, reﬂecting at least in part the
variability of baseline seropositivity and circulating serotypes, both of which aﬀect
the performance of the vaccine [19, 20]. At present, there is no antiviral therapy that
is available for the prevention and treatment of acute dengue virus infection. How-
ever, eﬀorts were still ongoing, for example, the cyclohexenyl chalcone derivatives
of a Zingiberaceae species, Boesenbergia Rotunda (L.) were reported to inhibit
DENV2 protease [6, 21]. Panduratin A and 4-hydroxypanduratin A, compounds iso-
lated from this plant were found to exhibit modest inhibitory activities, speciﬁcally
65e80% inhibition at 80 ppm (200 mM) [21]. In addition to natural products, repos-
itory libraries such as National Cancer Institute, USA (NCI) library which maintains
a large number of compounds from both synthetic and natural resources is a valuable
repository to source for potential anti-dengue compounds. In our preliminary unpub-
lished work, screening of NCI compounds (diversity sets) for anti-dengue properties
was carried out using the protease assay as described by Yusof and co-workers [22].
In this study, further eﬀorts were undertaken to synthesize compounds based on
structure-activity relationship modelling.
One of the important reasons contributing to the lack of antiviral drugs to treat
dengue would be the challenging nature of identifying chemical compounds with
speciﬁc activities. Previously, cytopathic and plaque reduction assays have been
used for the screening and evaluation of antiviral drugs [23, 24, 25]. These methods
are labor intensive, time consuming, non-speciﬁc and not amendable to screen large
numbers of compounds in a high-throughput manner [24, 26]. Although a new spe-
ciﬁc DENV protease activity detection system (DENPADS) was developed to
monitor DENV infection and simultaneously evaluate the eﬃcacy and cytotoxicity
of potential anti-DENV candidates in cells, it is diﬃcult to distinguish between the
speciﬁc inhibitory activity of the compound on DENV protease and cytotoxicity ef-
fects on cellular functions [27]. As such, development of robust screening methods
and the ability to evaluate large libraries of compounds are essential to rapidlyon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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assay technology developed to measure analytes using homogenous protocol [28]. In
this preliminary study, we have developed a NS2B/NS3 protease inhibition assay us-
ing AlphaScreen beads and followed by screening of the synthesized thioguanine
derivatives for their possible anti-dengue activities.2. Materials and methods
2.1. Reagents
Aprotinin, 6-thioguanine (2-amino-9H-purine-6-thiol) and other chemicals used in
the chemical synthesis were purchased from Sigma-Aldrich (Milwaukee, WI,
USA). AlphaScreen Detection Kit containing StrepTactin donor beads (5 mg/
ml), 10x buﬀer and nickel chelate acceptor beads (5 mg/ml) and white 384-well
Opti-plate were purchased from Perkin Elmer (Santa Clara, CA, USA). BOC-
Gly-Arg-Arg-AMC was purchased from Nacalai Tesque (Kyoto, Japan). Silica
gel F254 aluminium plate and silica gel F254 glass plate were purchased from
Merck (Darmstadt, Germany). Peptide substrate (GGGFKEFAAGRKSLTLNLI-
TEGGG) was synthesized and undergone quality control analysis using Mass
Spectrometry and HPLC by GenScript (NJ, USA). 4-ﬂuorobenzaldehyde, 4-
hydroxy-3-methoxybenzaldehyde, 3,5-dihydroxybenzaldehyde, and deuterated di-
methylsulfoxide (DMSO-D6) were purchased from Acros Organic (Geel,
Belgium). HEPES buﬀer, NaOH and NaCl solutions were purchased from Fisher
Scientiﬁc (Geel, Belgium). Panduratin A, a natural compound was isolated as pre-
viously described [21].2.2. Expression, puriﬁcation and activity of NS2B/NS3 protease
Dengue NS2B/NS3 protease enzyme was expressed and puriﬁed as previously
described [22]. Brieﬂy, NS2B/NS3 expression plasmid was propagated in Escheri-
chia coli strain XL 1-Blue MRF (Agilent Technologies, Santa Clara, CA).The
enzyme was isolated and puriﬁed using Ni2þ-NTA (nickel-nitrilotriacetic acid)
resin-based column. The speciﬁc proteolytic activity of NS2B/NS3 protease was
determined using similar formula as published for other proteases [29, 30]. Protease
assay using ﬂuorogenic peptide susbtrate (BOC-Gly-Arg-Arg-AMC) was also used
to determine the NS2B/NS3 inhibition activities of the controls and derivatives [22].
Brieﬂy, 100 mM of ﬂuorogenic peptide substrate and 0.57 mM protease enzyme in
200 mM Tris-HCl buﬀer (pH 8.5) were incubated with various concentrations of in-
hibitors for 1 h at 37 C. Cleavage of the substrate by NS2B/NS3 protease and detec-
tion of the ﬂuorescence signal were determined using Envision 2104 Multilabel Plate
Reader (Perkin Elmer, Boston, MA, USA) at excitation and emission wavelength of
385 nm and 465 nm, respectively. Three independent experiments were carried out.on.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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NS3 protease inhibitors
Based on an initial screening of NCI diversity chemical library, a NCI compound
known as diversity 0713 was found to be potentially active against DENV2
NS2B/NS3 protease. Diversity 0713 exhibits thioguanine scaﬀold, hence, fourteen
derivatives were modeled in silico. These model compounds were designed by add-
ing substituents at various positions (i.e., positions 1, 5, 7) of the thioguanine ring.
Brieﬂy, the structures of compounds were constructed using ACD/ChemSketch
Freeware Version 11.01 (Advanced Chemistry Development, Inc., Canada) and
optimized using PRODRG server (http://davapc1.bioch.dundee.ac.uk/prodrg/)
[31]. The homology model of NS2B/NS3 protease in complex with the peptide sub-
strate developed by Wichapong et al. was used in this in silico study [18]. Molecular
docking simulation was carried out using the AutoDock 4.2.6 software package [32]
with the docking ﬁles prepared using the AutoDockTools (ADT) 1.5.6 RC3 pack-
age. A grid map of 80  80  80 points at the position of 20, 40, -1 in the x, y, z
coordinates, with a spacing of 0.375 A between the grid points was set. The La-
marckian genetic algorithm (LGA) was used for the ligand conformational search
and 100 independent docking runs were applied for diversity 0713, panduratin A
and thioguanine derivatives, respectively. The docked conformations of the ligands
were ranked into clusters based on the increasing order of the binding free energy.
The molecular interactions of the ligands with NS2B/NS3 complex were analyzed
using Accelryls Discovery Studio Visualizer 3.5 (Accelrys, Inc., San Diego, CA,
USA). Parameters such as hydrogen bonding and hydrophobic interactions with
NS2B/NS3 residues, free energy of binding (FEB) and estimated inhibition constant
(Ki) of these compounds were compared with diversity 0713 and panduratin A.2.4. Synthesis of thioguanine derivatives
The synthesis of derivatives 1e11 and 12e14 was carried out as described by Sal-
vatore and co-workers and Panneerselvam and co-workers, respectively [33, 34]. 1H
and 13C-NMR spectra were determined using BrukerAvance 500 spectrometer
(Bruker, USA) with TMS as an internal standard. Mass spectra were determined
on XEVO-G2 QTOF#YCA153 (Waters, Milford, USA). The 3D X-ray crystal struc-
tures were resolved on Bruker SMART APEXII CCD (Bruker, USA). The melting
points were obtained from an electrothermal melting point apparatus. The synthesis
and characterization of thioguanine derivatives are as below:
9-ethyl-6-(ethylthio)-9H-purin-2-amine (1). Compound 2-amino-9H-purine-6-
thiol (0.1 g, 0.6 mmol) and Cs2CO3 (0.4 g, 1.3 mmol) were dissolved in DMF
(3.5 mL) and a mixture containing ethyl bromide (0.2 mL, 2.6 mmol), tetra-butylam-
monium iodide (TBAI) (0.5 g, 1.3 mmol) and DMF (3.5 mL) was added in small
portions. The mixture was allowed to stand for 4 h at room temperature, then pouredon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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organic layers were washed with water, dried over MgSO4 and evaporated in vacuo.
The residual crude product was chromatographed on silica gel with n-hexane: ethyl
acetate (1:3) to obtain 1 as a colorless amorphous (0.03 g, 19%), 1H-NMR (CDCl3):
dH 1.41 (t, 3H, J ¼ 7.5 Hz, 14-H3), 1.48 (t, 3H, J¼ 7.5 Hz, 11-H3), 3.31 (q, 2H, J¼
7.5 Hz, 13-H2), 4.11 (q, 2H, J¼ 7.5 Hz, 10-H2), 4.87 (br, s, 2H, NH2), 7.65 (s, 1H, 2-
H); 13C NMR (DMSO-d6): dC 15.5 (C-14), 15.6 (C-11), 22.3 (C-10), 38.3 (C-13),
124.6 (C-4), 140.7 (C-2), 151.1 (C-9), 159.7 (C-7), 159.96 (C-5); QTOF-MS m/z
calcd for C9H14N5S [MþH]þ224.3059.
9-isopropyl-6-(isopropylthio)-9H-purin-2-amine (2). Compound 2-amino-9H-pu-
rine-6-thiol (0.2 g, 1.2 mmol) and Cs2CO3 (0.9 g, 2.6 mmol) were dissolved in
DMF (7 mL) and a mixture containing isopropyl bromide (0.5 mL, 5.2 mmol),
tetra-butylammonium iodide (TBAI) (1.0 g, 2.6 mmol) and DMF (7 mL) was added
in small portions. The mixture was allowed to stand for 4 h at room temperature,
then poured into water (70 mL) and extracted with ethyl acetate (2  50 mL).
The combined organic layers were washed with water, dried over MgSO4 and evap-
orated in vacuo. The residual crude product was chromatographed on silica gel with
n-hexane: ethyl acetate (1:3) to obtain 2 as a colorless amorphous (0.05 g, 31%), 1H
NMR (CDCl3): dH 1.45 (d, 6H, J ¼ 6.5 Hz, 14-H3 and 17-H3), 1.55 (d, 6H, J ¼ 7.0
Hz, 11-H3 and 16-H3), 4.28 (m, 1H, J ¼ 7.0 Hz, 13-H), 4.67 (m, 1H, J ¼ 7.0 Hz,
10-H), 4.84 (br, s, 2H, NH2), 7.69 (s, 1H, 2-H); 13C NMR (CDCl3): dC 22.5 (C-14
and C-17), 23.3 (C-11 and C-16), 30.9 (C-13), 34.2 (C-10), 46.5 (C-4), 125.9 (C-2),
137.7 (C-9), 158.3 (C-7), 167.3 (C-5); QTOF-MS m/z calcd for C11H17N5NaS
[MþNa]þ274.3404.
6-(-2-ethylhexylthio)-9-(-2-ethylhexyl)-9H-purin-2-amine (3). Compound 2-
amino-9H-purine-6-thiol (0.2 g, 1.2 mmol) and Cs2CO3 (0.9 g, 2.6 mmol) were dis-
solved in DMF (7 mL) and a mixture containing 2-ethylhexyl bromide (0.9 mL, 5.3
mmol), tetra-butylammonium iodide (TBAI) (1.0 gram, 2.6 mmol) and DMF (7 mL)
was added in small portions. The mixture was allowed to stand for 24 h at room tem-
perature, then poured into water (70 mL) and extracted with ethyl acetate (2  50
mL). The combined organic layers were washed with water, dried over MgSO4
and evaporated in vacuo. The residual crude product was chromatographed on silica
gel with n-hexane: ethyl acetate (1:3) to obtain 3 as a colorless amorphous (0.1 g,
31%), Colorless amorphous, 1H NMR (CDCl3): dH 0.86e0.95 (m, 12H, 22-H, 15-
H, 27-H and 25-H), 1.26e1.33 (m, 12H, 19-H, 12-H, 20-H, 13-H, 26-H and 24-
H), 1.65e1.73 (m, 1H, 11-H), 1.84e1.91 (m, 1H, 18-H), 3.37e3.49 (m, 2H, 17a-
H and 10a-H), 3.88e4.00 (d, 2H, J ¼ 7.0 Hz, 17b-H and 10b-H), 4.81 (br, s, 4H,
NH2), 7.58 (s, 1H, 2-H); 13C NMR (CDCl3): dC 10.4 (C-27), 11.1 (C-25), 14.0
(C-22), 14.1 (C-15), 22.8 (C-21), 22.9 (C-14), 23.6 (C-24), 25.8 (C-26), 28.4 (C-
20), 28.9 (C-13), 30.2 (C-12), 30.9 (C-19), 32.2 (C-11), 32.6 (C-18), 39.3 (C-17),
39.5 (C-10), 125.7 (C-4), 140.2 (C-2), 150.7 (C-9), 158.7 (C-7), 161.9 (C-5).on.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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thiol (0.2 g, 1.2 mmol) and Cs2CO3 (0.9 g, 2.6 mmol) were dissolved in DMF (7
mL) and a mixture containing cyclopentyl bromide (0.2 mL, 2.2 mmol), tetra-buty-
lammonium iodide (TBAI) (1.0 g, 2.6 mmol) and DMF (7 mL) was added in small
portions. The mixture was allowed to stand for 4 h at room temperature, then poured
into water (70 mL) and extracted with ethyl acetate (2  50 mL). The combined
organic layers were washed with water, dried over MgSO4 and evaporated in vacuo.
The residual crude product was chromatographed on silica gel with n-hexane: ethyl
acetate (1:3) to obtain 4 as white powder (0.2 g, 62%), mp 160-162 C, 1H NMR
(CDCl3): dH 1.60e1.70 (m, 4H, 13-H and 14-H), 1.81 (m, 2H, 12-H), 2.02 (m,
2H, 15-H), 4.32 (m, 1H, 11-H), 4.92 (br, s, 2H, NH2), 7.78 (s, 1H, 2-H); 13C
NMR (CDCl3): dC 24.9 (C-13 and C-14), 33.6 (C-12 and C-15), 42.0 (C-11),
124.5 (C-4), 137.5 (C-2), 150.8 (C-9), 158.9 (C-7), 162.9 (C-5).
9-cyclopentyl-6-(cyclopentylthio)-9H-purin-2-amine (5). Compound 2-amino-
9H-purine-6-thiol (0.1 g, 0.6 mmol) and Cs2CO3 (0.4 g, 1.3 mmol) were dissolved
in DMF (3.5 mL) and a mixture containing cyclopentyl bromide (0.3 mL, 2.6 mmol),
tetra-butylammonium iodide (TBAI) (0.5 g, 1.3 mmol) and DMF (3.5 mL) was
added in small portions. The mixture was allowed to stand for 24 h at room temper-
ature, then poured into water (70 mL) and extracted with ethyl acetate (2  50 mL).
The combined organic layers were washed with water, dried over MgSO4 and evap-
orated in vacuo. The residual crude product was chromatographed on silica gel with
n-hexane: ethyl acetate (1:3) to obtain 5 as white powder (0.1 g, 72%), mp 129-131
C, 1H NMR (CDCl3) dH 1.67e1.70 (m, 4H, 18-H and 19-H), 1.70e1.80 (m, 4H,
12-H and 13-H), 1.91e2.21 (m, 4H, 17-H and 20-H), 2.21e2.26 (m, 4H, 11-H
and 14-H), 4.71e4.76 (m, 1H, 16-H), 4.77e4.98 (m, 1H, 10-H), 4.83 (s, 2H,
NH2), 7.67 (s, 1H, 2-H); 13C NMR (CDCl3): dC 23.8 (C-12 and C-13), 24. 9 (C-
18 and C-19), 32.6 (C-11 and C-14), 33.6 (C-17 and C-20), 55.3 (C-16 and C-
10), 126.0 (C-4), 138.0 (C-2), 150.5 (C-9), 158.7 (C-7), 162.5 (C-5); QTOF-MS
m/z calcd for C15H22N5S [MþH]þ304.4336.
Methyl {[2-amino-9-(2-methoxy-2-oxoethyl)-9H-purin-6-yl]sulfanyl} acetate
(6). Compound (2-amino-9H-purine-6-thiol (0.2 g, 1.2 mmol) and Cs2CO3 (0.4 g,
1.3 mmol) were dissolved in DMF (3.5 mL) and a mixture containing methyl bro-
moacetate (0.3 mL, 2.6 mmol), tetra-butylammonium iodide (TBAI) (0.5 g, 1.3
mmol) and DMF (3.5 mL) was added in small portions. The mixture was allowed
to stand for 24 h at room temperature, then poured into water (70 mL) and extracted
with ethyl acetate (2  50 mL). The combined organic layers were washed with wa-
ter, dried over MgSO4 and evaporated in vacuo. The residual crude product was
chromatographed on silica gel with n-hexane: ethyl acetate (1:3) to obtain 6 as white
powder (0.2 g, 58%), mp 139-141 C, 1H NMR (CDCl3) dH 3.75 (s, 3H, 19-H3), 3.79
(s, 3H, 13-H3), 4.09 (s, 2H, 16-H2), 4.82 (s, 2H, 10-H2), 4.89 (br, s, 2H, NH2), 7.69
(s, 1H, 2-H); 13C NMR (CDCl3): dC30.7 (C-19), 43.7 (C-13), 52.7 (C-16), 52.9 (C-on.2018.e01023
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169.7 (C-17); QTOF-MS m/z calcd for C17H14N5O4S [MþH]þ312.3249.
6-{[(pyridin-2-yl)methyl]sulfanyl}oolpl.-9H-purin-2-amine (7). Compound 2-
amino-9H-purine-6-thiol (0.1 g, 0.6 mmol) and Cs2CO3 (0.4 g, 1.3 mmol) were dis-
solved in DMF (3.5 mL) and a mixture containing methyl pyridinium bromide hy-
drobromide (0.3 g, 1.3 mmol), tetra-butylammonium iodide (TBAI) (0.5 g, 1.3
mmol) and DMF (3.5 mL) was added in small portions. The mixture was allowed
to stand for 24 h at room temperature, then poured into water (70 mL) and extracted
with ethyl acetate (2  50 mL). The combined organic layers were washed with wa-
ter, dried over MgSO4 and evaporated in vacuo. The residual crude product was
chromatographed on silica gel with n-hexane: ethyl acetate (1:3) to obtain 7 as white
powder (0.08 g, 53%), mp 260-263 C, 1H NMR (DMSO-d6) dH 4.65 (s, 2H, 11-H2),
6.46 (s, 2H, NH2), 7.26e7.91 (m, 4H, 17-H, 16-H, 15-H and 14-H), 8.51 (s, 1H, 2-
H),12.57 (s, 1H, 1-H); 13C NMR (DMSO-d6): dC 33.6 (C-11), 122.7 (C-15), 123.9
(C-17), 137.2 (C-4), 137.6 (C-16), 139.3 (C-2), 141.9 (C-14), 149.6 (C-9), 152.3 (C-
12), 158.3 (C-7), 160.0 (C-5).
6-(benzylsulfanyl)-9H-purin-2-amine (8). Compound 2-amino-9H-purine-6-thiol
(0.1 g, 0.6 mmol) and Cs2CO3 (0.4 g, 1.3 mmol) were dissolved in DMF (3.5
mL) and a mixture containing benzyl bromide (0.2 mL, 1.3 mmol), tetra-butylam-
monium iodide (TBAI) (0.5 g, 1.3 mmol) and DMF (3.5 mL) was added in small
portions. The mixture was allowed to stand for 12 h at room temperature, then
poured into water (70 mL) and extracted with ethyl acetate (2  50 mL). The com-
bined organic layers were washed with water, dried over MgSO4 and evaporated in
vacuo. The residual crude product was chromatographed on silica gel with n-hexane:
ethyl acetate (1:3) to obtain 8 as white powder (0.1 g, 74%), m.p. 193-195 C [195
C [1]], 1H NMR (DMSO-d6) dH 5.44 (s, 2H, 11-H2), 5.67 (s, 2H, NH2), 7.33 (m,
6H, 13-H, 17-H, 15-H, 14-H, 16-H and 2-H), 9.65 (s, 1H, 1-H); 13C NMR
(DMSO-d6): dC 32.8 (C-11), 114.0 (C-13 and C-17), 134.2 (C-15), 134.6 (C-14
and C-16), 137.5 (C-4), 139.8 (C-12), 141.3 (C-2), 149.9 (C-9), 157.6 (C-7),
159.8 (C-5).
9-benzyl-6-(benzylsulfanyl)-9H-purin-2-amine (9). Compound (2-amino-9H-pu-
rine-6-thiol (1.0 g, 5.9 mmol) and Cs2CO3 (4.3 g, 13 mmol) were dissolved in
DMF (25 mL) and a mixture containing benzyl bromide (3.1 mL, 26.3 mmol),
tetra-butylammonium iodide (TBAI) (5.0 g, 1.3 mmol) and DMF (25 mL) was
added in small portions. The mixture was allowed to stand for 24 h at room temper-
ature, then poured into water (70 mL) and extracted with ethyl acetate (2  50 mL).
The combined organic layers were washed with water, dried over MgSO4 and evap-
orated in vacuo. The residual crude product was chromatographed on silica gel with
n-hexane: ethyl acetate (1:3) to obtain 9 as blocked crystal from methanol (1.4 g,
68%), mp 155-157 C [157 C [2]], 1H NMR (CDCl3): dH 4.50 (s, 2H, NH2),on.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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21-H, 23-H, 13-H, 15-H, 22-H, 14-H), 7.52 (s, 1H, 2-H); 13C NMR (CDCl3): dC
32.6 (C-18), 46.6 (C-10), 127.2 (C-14), 127.6 (C-20 and C-24), 128.3 (C-13 and
C-15), 128.5 (C-23 and C-21), 129.0 (C-12 and C-16), 129.1 (C-4), 135.6 (C-11),
137.8 (C-19), 139.9 (C-2), 150.8 (C-9), 158.9 (C-7), 161.7 (C-5).
N, 9-dibenzyl-6-(benzylsulfanyl)-9H-purin-2-amine (10). Compound 2-amino-
9H-purine-6-thiol (0.1 g, 0.6 mmol) and Cs2CO3 (1.4 g, 3.9 mmol) were dissolved
in DMF (12.5 mL) and a mixture containing benzyl bromide (0.5 mL, 3.9 mmol),
tetra-butylammonium iodide (TBAI) (1.5 g, 3.9 mmol) and DMF (12.5 mL) was
added in small portions. The mixture was allowed to stand for 48 h at room temper-
ature, then poured into water (70 mL) and extracted with ethyl acetate (3  70 mL).
The combined organic layers were washed with water, dried over MgSO4 and evap-
orated in vacuo. The residual crude product was chromatographed on silica gel with
n-hexane: ethyl acetate (1:3) to obtain 10 as white powder (0.07 g, 25%), mp 132-
134 C, 1H NMR (CDCl3): dH 4.45 (s, 2H, 18-H12), 4.63 (s, 2H, 26-H2), 5.14 (s,
2H, 10H2), 5.34 (s, 1H, NH), 7.14e7.50 (m, 15H, 20-H, 24-H, 28-H, 32-H, 12-
H, 16-H, 22-H, 30-H, 14-H, 21-H, 23-H, 29-H, 31-H, 13-H and 15-H), 7.51 (s,
1H, 2-H); 13C NMR (CDCl3): dC 32.5 (C-18), 46.0 (C-26), 46.7 (C-10), 127.4
(C-22), 127.8 (C-30), 128.2 (C-14), 128.4 (C-20), 128.5 (C-24), 128.6 (C-28 and
C-32), 128.7 (C-12 and C-16), 128.8 (C-21 and C-23), 128.9 (C-29 and C-31),
129. 0 (C-13 and C-15), 135.9 (C-11), 137.9 (C-19), 139.5 (C-27), 150.6 (C-2),
158.8 (C-9), 160.7 (C-7), 165.0 (C-5); QTOF-MS m/z calcd for C26H23N5S [M
]þ437.5593, found 437.2747.
Continued elution with n-hexane: ethyl acetate (1:3) resulted in 11 (N, N, 9-
tribenzyl-6-(benzylsulfanyl)-9H-purin-2-amine) as a brown liquid (0.2 g, 70%),
1H NMR (CDCl3): dH 4.45 (s, 8H, 18-H, 26-H, 33-H and 10-H), 7.21e7.38 (m,
20H, 20-H e 24-H, 28-H e 32-H, 35-H e 39-H and 12-H e 16-H); 13C NMR
(CDCl3): dC (CDCl3) 33.6 (C-18), 65.4 (C-26 and C-33), 72.1 (C-10), 127.6 (C-
30, C-27 and C-22), 127.8 (C-24 and C-20), 127.9 (C-28, C-32, C-35 and C-39),
128. 4 (C-29, C-31, C-36 and C-38), 128.7 (C-21 and C-23), 128.8 (C-13 and C-
15), 129.7 (C-12 and C-16), 129.9 (C-4), 131.6 (C-11, C-34 and C-27), 133.2 (C-
19), 134.5 (C-2), 137.8 (C-9), 138.3 (C-7), 139.3(C-5); QTOF-MS m/z calcd for
C33H29N5S [M ]
þ527.6818, found 527.3339.
2-(4-ﬂuorobenzylideneamino)-9H-purine-6-thiol (12). Compound 2-amino-9H-
purine-6-thiol (0.1 g, 0.6 mmol) was mixed with 4-ﬂuorobenzaldehyde (0.06 mL,
0.6 mmol), stirred for 15 min and the liquid mixture of ethanol and 10% (v/v)
NaOH [3.0 mL (1:1)] was added in small portions. The mixture was allowed to stand
for 2 h at 80 C, then neutralized with HCl (6 M) until precipitated. The solid product
was ﬁltered, washed with water followed by ethyl acetate. The residual crude prod-
uct was chromatographed on silica gel with CHCl3: methanol (2:2) to obtain 12 ason.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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dH 7.32 (dd, 2H, J¼ 8.5 Hz, J¼ 4.0 Hz, 15-H and 17-H), 7.34 (s, 1H, 2-H), 7.78 (s,
1H, 12-H), 7.87 (m, 2H, 14-H and 18-H); 13C NMR (CDCl3): dC 116.1 (C-15 and
C-17), 116.3 (C-13), 125.8 (C-14 and C-18), 130.3 (C-4), 130.4 (C-2), 131.0 (C-7),
142.1 (C-9), 163.1 (C-12), 165.1 (C-16), 188.5 (C-5); QTOF-MS m/z calcd for
C12H8FN5S [MþH]þ274.2976.
2-methoxy-4-{[(6-sulfanyl-9H-purin-2-yl)imino]methyl}phenol (13). Compound
2-amino-9H-purine-6-thiol (0.1 g, 0.6 mmol) was mixed with 4-hydroxy-3-
methoxybenzaldehyde (0.09 g, 0.6 mmol), stirred up for 15 minutes and the liquid
mixture of ethanol and NaOH 10% [3.0 mL (1:1)] was added in small portions. The
mixture was allowed to stand for 2 h at room temperature, then neutralized with HCl
(6 M) until precipitated. The solid product was ﬁltered, washed with water followed
by ethyl acetate. The residual crude product was chromatographed on silica gel with
methanol (100%) to obtain 13 as white powder (0.08 g, 45%), decomps. 300 C, 1H-
NMR (DMSO-d6): dH 3.85 (s, 3H, OMe), 7.126 (br, s, 3H, 17-H, 14-H and 18-H),
8.16 (s, 1H, 2-H), 8.28 (s, 1H, 12-H), 12.59 (br, s, 1H, 1-H); 13C NMR (DMSO-d6):
dC 84.1 (C-20), 127.5 (C-17), 133.1 (C-14), 140.3 (C-18), 155.0 (C-4), 155.1 (C-2),
155.2 (C-16), 161.1 (C-15), 161.4 (C-7), 163.2 (C-9), 168.5 (C-12), 172.4 (C-5).
5-{[(6-sulfanyl-9H-purin-2-yl)imino]methyl}benzene-1,3-diol (14). Compound
2-amino-9H-purine-6-thiol (0.1 g, 0.6 mmol) was mixed with 3,5-
dihydroxybenzaldehyde (0.08 g, 0.6 mmol), stirred up for 15 minutes and the liquid
mixture of ethanol and NaOH 10% [3.0 mL (1:1)] was added in small portions. The
mixture was allowed to stand for 2 h at room temperature, then neutralized with HCl
(6 M) until precipitated. The solid product was ﬁltered, washed with water followed
by ethyl acetate. The residual crude product was chromatographed on silica gel with
CH2Cl2: methanol (2:2) to obtain 14 as brown powder (0.05 g, 29%), decomps. 300
C, 1H NMR (DMSO-d6): dH 7.02 (br, s, 3H, 16-H, 14-H and 18-H), 8.14 (s, 1H, 12-
H), 8.74 (s, 1H, 2-H), 12.51 (br, s, 1H, 1-H); 13C NMR (DMSO-d6): dC 95.6 (C-16),
97.4 (C-14 and C-18), 121.0 (C-4), 141.0 (C-13), 147.6 (C-2), 148.9 (C-7), 154.6
(C-9), 160.2 (C-15 and C-20), 170.0 (C-12), 172.0 (C-5); QTOF-MS m/z calcd
for C12H13N6O2S [MþNH4]þ305.3356.2.5. AlphaScreen assay optimization and screening of
derivatives
The peptide substrate used in this assay has a known NS2B/NS3 cleavage site be-
tween lysine (K), and serine (S) (GRK Y SLT), and is a part of a sequence of dengue
polyprotein precursor (NS3/NS4A) as reported by Khumtong and co-workers [35,
36]. The peptide substrate was tagged with a speciﬁc sequence (WSHPQFEKSA)
at N-terminal and polyhistidine at C-terminal. This speciﬁc sequence has a binding
aﬃnity towards StrepTactin, an engineered streptavidin [37]. Glycine linkers wereon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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extent of N-terminal labelling on the peptide substrate, competitive displacement
assay using AlphaScreen TruHits Detection Kit (Perkin Elmer, USA) consisting
of StrepTactin donor beads and biotinylated acceptor beads was carried out. On
the other hand, to ensure that the peptide substrate is adequately tagged with poly-
histidine on the C-terminal, competitive binding assay using Histidine (Nickel
Chelate) Detection Kit (Perkin Elmer, USA) was carried out. This kit comprises
of both StrepTactin donor beads and nickel chelate acceptor beads.
In general, AlphaScreen experiments were carried out in white 384-well plates
(Perkin Elmer, Boston, MA, USA) in a total reaction volume of 25 mL under sub-
dued light. All dilutions were initially performed in starting assay solution contain-
ing 25 mM HEPES buﬀer (pH 7.4), 100 mM NaCl and 0.01 % (w/v) BSA.
StrepTactin donor beads and nickel chelate acceptor beads were used at ﬁnal con-
centration of 20 mg/mL. The 384-well plate was read using Envision 2104 Multilabel
Plate Reader (Perkin Elmer, Boston, MA, USA) according to AlphaScreen settings
(excitation and emission wavelength at 680nm and 520-620nm, respectively). ForFig. 1. (a) The peptide substrate used in this assay is tagged with a speciﬁc sequence at N-terminal and
His-tag at C-terminal (b) An illustration showing the interaction between the peptide substrate and the
AlphaScreen beads.
on.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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titrated to determine the concentrations that generate optimal AlphaScreen signals.
Brieﬂy, in each well, 5 mL of peptide substrate and NS2B/NS3 protease enzyme
were mixed with 5 mL assay buﬀer and incubated at 37 C. After incubating for 1
h, 5 mL of donor beads and acceptor beads were added, followed by 1 h incubation
at room temperature prior to reading of signal. To develop an assay that delivers high
signal and low background, diﬀerent buﬀer system, various concentrations of
HEPES, NaCl and BSA, pH and incubation time were optimized. The optimum con-
ditions were determined based on the maximum signal obtained from well contain-
ing peptide alone and minimum signal produced by well containing peptide
substrate, enzyme and beads, indicating maximum cleavage of the NS2B/NS3
enzyme on the substrate and lowest background signal. Once the assay was opti-
mized, it was used to screen the compounds for their potential NS2B/NS3 protease
inhibition activity. Aprotinin and panduratin A were used as positive controls. Since
the amount obtained for diversity 0713 was in minute quantity and was insuﬃcient
for subsequent testing, diversity 0713 was not used as control in this study. All com-
pounds were dissolved in DMSO and the assay was performed in either 1% (v/v) or
10% (v/v) DMSO in ﬁnal concentrations, depending on the solubility of the thiogua-
nine derivatives.2.6. Data analysis
IC50 values were derived based on non-linear regression analysis computed using
GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA). All data were pre-
sented as mean  SD. The zʹ factor was calculated as described by Zhang and co-
workers [38]. zʹ factor ¼ 1e3(sHþsL)/jmHmLj, where sH and sL represent
the standard deviations of the AlphaScreen signal of the substrate in the absence
(high signal, H) and presence (low signal, L) of the protease, and mH and mL repre-
sent the mean values of high signal and low signal, respectively. To evaluate the
robustness of the assay, interday variations were evaluated in assay plate replicates
and coeﬃcient variation (CV) was calculated using the formula; % CV ¼ (SD/On)/
average x 100.3. Results
3.1. Molecular docking
Docking simulation of diversity 0713 compound within the active site of DENV2
NS2B/NS3 protease showed an interaction with N152, a sub-pocket 2 residue.
This compound was also observed to interact with G151 and G153 by forming
hydrogen bonds and Y150 and Y161 via hydrophobic bonds. The calculated FEB
and the estimated inhibition constant (Ki) for diversity 0713 was 6.64 kcal/molon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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within the active site of dengue NS2B/NS3 protease revealed that it interacts with
G151 and G153 of the NS2B/NS3 protease, similar to the previous work carried
out by Lee and co-workers (Fig. 2) [39]. Panduratin A also has similar interactions
as diversity 0713, such as hydrogen bonds formation with G151 and G153 and hy-
drophobic bonds with Y150 and Y161 residues, respectively. However, the calcu-
lated FEB and Ki for panduratin A were slightly lower than diversity 0713
compound at -6.93 kcal/mol and 8.36 mM, respectively, indicating that panduratin
A may probably have similar inhibitory activity as diversity 0713 compound.
On the other hand, thioguanine derivatives exhibited binding interactions with
important residues such as sub-pockets (1 and 2) of dengue NS2B/NS3 protease.
Nine out of fourteen compounds (Compounds 1, 2, 3, 4, 6, 7, 8, 12, and 13)
have FEB and estimated Ki values higher than panduratin A. Compounds 5, 9,
10, 11 and 14 have lower FEB and Ki values as compared with panduratin A, sug-
gesting greater inhibitory activity against the dengue protease (Table 1). Generally,
the molecular interactions of these derivatives with the protease have some similar-
ity with panduratin A, for example most compounds form hydrogen bonding and/
or hydrophobic interactions with G151 and G153 residues and have hydrophobic
interactions with at least one of the catalytic triad residues (H51, D75, and S135).
Brinkworth and co-workers have stressed the importance of G153 residues in over-
all substrate binding [40]. Only compounds 1, 6, 10 and 14 forms hydrogen bonds
with at least one of the catalytic triad residues (H51, D75, and S135). These resi-
dues are important because they are involved in the cleavage of the viral polypro-
tein. In addition, most of the model compounds were demonstrated to interact with
N152, one of the residues found in the sub-pocket 2. None of the compounds were
observed to interact with residues in sub-pocket 3 (F85, Q86 and L87) or sub-
pocket 4 (V154). Compound 11 scored the lowest FEB and Ki value but its binding
orientation is slightly diﬀerent from panduratin A as it interacts with both G151
and Y161 (sub-pocket 1). However, both compounds have hydrophobic interac-
tions with all three catalytic triad residues (Table 1). Based on the molecular dock-
ing simulation, all fourteen model compounds were found to be potentially active
against NS2B/NS3 protease; hence, these compounds were synthesized for further
evaluation.3.2. Synthesis and characterization of thioguanine derivatives
The synthesis of thioguanine derivatives was divided into 2 types of reaction, alkyl-
ation (N-alkylation and S-alkylation) and Schiﬀ base formation. The alkylation was
carried out by reacting thioguanine and alkyl bromide. In this reaction, the chemo
selective S-alkylation (4, 7 and 8) was applied by using tetrabutyl ammonium iodide
(TBAI) as phase transfer catalyst (PTC) while cesium carbonate (Cs2CO3) was usedon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Table 1. Summary of molecular interactions of panduratin A and 14 derivatives (100 docking runs).
Compound NS2B/NS3 protease residue FEB
(kcal/mol)
Estimated
Inhibition
Constant,
Ki (mM)
Hydrogen bonding Hydrophobic i
nteractions
S1 S2 S3 S4 Others S1 S2 S3 S4 Others
Panduratin A G151, G153,
D81, G82
S135(2), Y150,
Y161(5)
D75,
N152(7)
V154(2) H51(2), D81, G82(2), S83,
M84, F130, G151(3),
G153(8), V155(2)
-6.93 8.36
Diversity 0713 N152 G151, G153 Y150, Y161 -6.64 13.49
1 S135 F130, S131 D129(3), S135(2),
Y150(4), Y161(7)
F130(4), S131(2), P132(3),
T134(3), G151(2)
-4.80 303.19
2 N152 G151, G153 S135(3), Y150,
Y161(9)
N152(6) V154(2) H51, P132, G151(3),
G153(4), V155(2)
-5.51 91.38
3 N152 G151, G153 135(3), Y150(1),
Y161(8)
N152(6) V154 H51, M84, I86, F130(3),
S131(2), P132(3), G151(6),
G153(7), 155(4)
-6.37 21.49
4 N152 G151, G153 S135(2), Y150,
Y161(8)
N152(5) H51, F130(2), S131,
G151(7), G153(3)
-6.03 37.89
5 N152 G151, G153 S135(2), Y150(2),
Y161(8)
N152(6) V154(2) H51, M84, F130(3), S131,
T134, G151, G153(5),
V155(2)
-7.52 3.08
6 S135 N152 G151, G153,
V155
S135, Y150, V154(3),
Y161(8)
N152(6) M84, S131, P132, G151(4),
G153(5), V155(2)
-5.06 195.64
7 N152 G151, G153,
P132
S135(2), Y150(2),
Y161(8)
N152(4) V154(2) F130(2), S131(2), P132(2),
T134(2), G151(2), G153(7),
V155(2)
-6.42 19.72
8 N152 G151, G153 S135(2), Y150(2),
Y161(9)
N152(5) V154(2) P130(3), S131(3), P132(2),
T134(2), G151(2), G153(7),
V155(2)
-6.79 10.54
(continued on next page)
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Table 1. (Continued )
Compound NS2B/NS3 protease residue FEB
(kcal/mol)
Estimated
Inhibition
Constant,
Ki (mM)
Hydrogen bonding Hydrophobic i
nteractions
S1 S2 S3 S4 Others S1 S2 S3 S4 Others
9 N152 G151, G153 S135, Y150(3),
Y161(7)
N152 (5) V154 S83(2), M84(2), P130(3),
S131(3), P132(2), T134(2),
G151, G153(7), V155
-7.10 6.29
10 S135 S135 (5), Y150,
Y161(7)
N152 I36(2), V52, F130, S131,
P132(4), G151(5), G153(4),
V155(2)
-7.53 3.02
11 Y161 G151 S135(5), Y150(2),
Y161(6)
D75(3),
N152
I36(2), W50(2), H51(16),
V52, V72(2), D81(2), G82(2),
F130(2), S131(2), P132(4),
T134, G151(2), G153, V155
-8.88 0.311
12 Y161 G151, G153,
W50, G82, M84
Y161 D75(2),
N152(7)
W50(3), H51, V72(4),
D81(7), G82, S83, M84,
G151(3), G153(3)
-6.90 8.70
13 Y161 G151, G153, W50,
G82, M84
Y161 D75(2),
N152(6)
W50 (5), V72 (4), D81 (8),
G82, S83 (2), M84, G151 (3),
G153
-6.51 16.86
14 S135, D129 G153, F130, T134 S135(3), Y150(4),
Y161(7)
N152(6) S83(2), M84, F130(3),
S131(2), T134(2), G151(4),
G153(5)
-6.94 8.16
Sub-pocket residues: S1 (D129, S135, Y150, Y161), S2 (D75, D82, G83, N84, N152), S3 (F85, Q86, L87), S4 (V154), Catalytic triad (H51, D75, S135). *Number in bracket ( ) represent the
number of hydrophobic interactions formed.
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Fig. 2. Molecular docking of panduratin A in the active site of the serine protease domain of the NS2B/
NS3 protease. The conformation of compounds is shown in ball and stick representation. Atoms are
colored grey for carbon, blue for nitrogen, brown for sulfur, red for oxygen and white for hydrogen.
Hydrogen bonds are depicted as a green line. NS2B/NS3 protease is represented as yellow ribbon. Res-
idues labeled in purple are those that involved in hydrophobic interactions, while those in green are
involved in hydrogen bonding and hydrophobic interactions.
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employed as the solvent in the N-alkylation. Further alkylation at NH (1-3, 5, 6 and
9) as well as NH2 (10 and 11) required at least 2-fold of alkyl bromide mole number.
The second series of the thioguanine derivatives (12-14) were synthesized based on
the reaction between primary amine of thioguanine and a diverse aromatic aldehyde
in a mixture of NaOH-ethanol solution. The structures of the synthesized compounds
are shown in Fig. 3.3.3. Optimization of the assay
The NS2B/NS3 protease enzyme was expressed and puriﬁed as described previously
(Fig. 4). The speciﬁc activity of the expressed NS2B/NS3 protease enzyme was
determined at 12 mU/mg and the concentration of the protease was 0.6 mg/ml. A
typical sigmoidal curve was observed in the TruHits competitive assay indicating
displacement of biotinylated acceptor beads from the donor beads by the peptide
substrate (Fig. 5a). Displacement of the biotinylated acceptor beads at low substrate
concentrations indicated that the substrate was adequately tagged with
WSHPQFEKSA sequence (EC50 value at 7 mM). Similarly, the extent of polyhisti-
dine tagging on the substrate was determined and based on the titration curve, signal
increased proportionally to the amount of peptide substrate present, as shown in
Fig. 5b, indicating that the substrate was adequately bound onto nickel chelate
acceptor beads at low concentrations (EC50 value at 0.11 mM).on.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 3. The structures of the synthesized thioguanine derivatives.
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shaped curve illustrating the hook eﬀect when the concentration of peptide substrate
was greater than 300 nM. Beyond this point, saturation of the peptide substrate with
the beads caused a decrease in signal intensity. In addition, increasing concentration
of enzyme produced a reduction in signal, indicating proteolytic activity of the
NS2B/NS3 enzyme. A signiﬁcant decrease in signal was observed from 100 nM on-
wards. The peptide substrate was almost completely cleaved in the presence of 3 mMon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 4. SDS-PAGE of fractions obtained from puriﬁcation of DENV2 protein precursor on Ni2þ-NTA
column; Lane M: protein molecular weight marker; Lane 1, 2, 3, 4, 5, 6 and 7 are the fractions eluted
from Ni2þ-NTA column; Lane C is control.
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300 nM of substrate were used in subsequent assays.
Initially, a starting buﬀer consisting of 25 mMHEPES, 100 mMNaCl, 0.01% (w/v)
BSA, pH 7.4) was used. However, the assay buﬀer was re-optimized to increase
signal/background (S/B) ratios. Eventually, 10 mM Hepes (pH 9.0), 20 mM
NaCl and 0.2% BSA provided the most robust assay conditions. The addition of
BSA improved the signal by a few hundred thousand counts per second
(Fig. 5deg). To evaluate the protein digestion duration, a time course experiment
was carried out and based on the results, a 24 h incubation time was found to be
optimal. At this point, the proteolytic activity was the highest (lowest signal in
the presence of enzyme) and background signal generated was also the lowest
(Fig. 5h).3.4. Screening of thioguanine derivatives using AlphaScreen
assay
DMSO was used for preparing the stock solution of the compounds. Majority of the
compounds were screened in the presence of 1% v/v DMSO, however, higher con-
centration of DMSO (10% v/v) was used for compounds with low solubility such as
compound 8, 9, 10, 11 and 12. There were no signiﬁcant diﬀerences in the alpha
signal obtained between assays run in 1% v/v and up to 10% v/v DMSO. Using
the AlphaScreen assay, aprotinin exhibited dose dependent inhibition against
NS2B/NS3 enzyme with an IC50 value of 0.35 mM (Fig. 6a), which was comparable
with the IC50 value generated by the protease assay (0.15 mM) (Fig. 6b). As for pan-
duratin A, the maximum inhibition at the highest concentration tested (100 mM) in
the AlphaScreen assay was just slightly above 50%, therefore, an IC50 value could
not be determined within the concentration range used (Fig. 6c). On the other hand,
the protease assay produced an IC50 value of 211.5 mM, which was expected
(Fig. 6d). However, most of the derivatives were found to have no clear activity
against NS2B/NS3 except compound 4 which demonstrated a weak activity. Bothon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 5. Titration curve of the competitive displacement assay to determine the extent of labelling on the
peptide substrate. (a) Displacement of biotinylated acceptor beads from the StrepTactin donor beads by
the peptide substrate (b) Bridging of the the StrepTactin donor beads and the nickel-chelated donor
beads by the peptide substrate, increasing the concentration of substrate results in an increase of signal
(c) Cross-titration curve of the peptide substrate and NS2B/NS3 protease which a hook point was reached
at 300 nM of peptide substrate. (d) Optimization of HEPES concentration (e) Optimization of NaCl con-
centration (f) Optimization of BSA concentration (g) Optimization of pH of assay solutions (h) Optimi-
zation of incubation time. All data are presented as mean alphasignal  SEM of triplicates of a single
independent experiment. Buﬀer-Yellow; Peptide-Purple; Peptide and enzyme-Red.
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50% at the highest concentration tested (1 mM) (Fig. 6e and f). Higher concentra-
tions of the both panduratin A and compound 4 were not tested using Alphascreen
assay as the estimated IC50 values would be too high to qualify the compounds ason.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 6. (a) The eﬀect of aprotinin on the NS2B/NS3 protease activity using AlphaScreen assay (IC50
value at 0.35 mM) (b) The eﬀects of aprotinin on the NS2B/NS3 protease activity using protease assay
(IC50 value at 0.15 mM) (c) The eﬀect of panduratin A on the NS2B/NS3 protease activity using
AlphaScreen assay (IC50 undetermined) (d) The eﬀect of panduratin A on the NS2B/NS3 protease ac-
tivity using protease assay (IC50 value at 211.5 mM) (e) The eﬀect of compound 4 on the NS2B/NS3
protease activity using AlphaScreen assay (IC50 undetermined) (f) The eﬀect of compound 4 on
NS2B/NS3 protease activity using protease assay (IC50 undetermined). Data are presented as mean al-
phasignal  SEM of three independent experiments.
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compounds are depicted in Fig. 7.
The interday variations were evaluated in assay plate replicates, with each plate
containing wells of minimum and maximum signal controls. The mean value for
the maximum signal groups on day 1, 2, 3 for aprotinin were 1.14 million cps
(CV ¼ 2.27%), 1.03 million cps (CV ¼ 0.15%) and 1.30 million cps (CV ¼
3.49%), respectively. On the other hand, the mean value for the minimum signal
was 5688 cps (CV ¼ 3.90%), 6024 cps (CV ¼ 5.41%), and 7256 cps (CV ¼
8.27%), respectively. The mean S/B ratio for aprotinin was 205:1. Similarly, theon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 7. The eﬀects of compounds on the NS2B/NS3 protease activity using AlphaScreen assay. Data
are presented as mean alphasignal  SEM of three independent experiments.
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1.67 million cps (CV ¼ 3.15%), 1.27 million cps (CV ¼ 2.61%) and 1.11 million
cps (CV ¼ 1.18%), respectively. Meanwhile, the mean value for the minimum
signal was 6199 cps (CV ¼ 6.22%), 3956 cps (CV ¼ 4.22%), and 5191 cps (CV
¼ 9.89%), respectively. The mean S/B ratio for panduratin A was 265:1. The inter-
day variability of both maximum and minimum signals was generally less than
10%. Finally, the zʹ factor value for three independent experiments were calculated
to determine the robustness and the quality of the developed assay. The individual
zʹ factor of the optimized assay ranged between 0.36 to 0.65 for aprotinin,on.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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useful for screening for anti-dengue activities [38, 41].4. Discussion
Dengue infection is a global health problem and according to WHO, an approxi-
mately 40% of the world population are at risk of dengue infection [42]. The highest
number of dengue cases that are mostly aﬄicted by DENV2 is reported from the
South East Asian countries [43, 44]. Currently, small molecules drugs [6, 45], pep-
tide drugs [46] and plant-derived medications or herbal medicines research for the
treatment of dengue infection is gaining much interest [6, 21, 47, 48, 49]. However,
the development of antiviral drugs to treat dengue infections remains a challenge,
due to the limited in vitro high-throughput screening assays and suitable in vivo
models to screen for anti-dengue drugs [50]. At present, no speciﬁc treatment, drugs
and vaccine are available to protect human against dengue infection.
There are intensive eﬀorts to develop drugs targeted against structural and/or
nonstructural proteins involved in dengue viral replication, along with the develop-
ment of vaccine. The ﬁrst dengue vaccine, Dengvaxia by Sanoﬁ Pasteur was
registered in Mexico in December, 2015 but was reported to cause antibody depen-
dent enhancement (ADE) and severe diseases in some cases [19, 20]. Meanwhile,
other candidate vaccines such as PDK-53 vaccine [51] and rDEN4D30(ME) [52]
were evaluated in clinical trials with unremarkable outcome. Development of pep-
tide inhibitors targeting on NS2B/NS3 protease and DENV entry such as aldehyde
peptide [53, 54], Bz-Nle-Lys-Arg-Arg-H [18], DET1-DET4 [55] and natural prod-
ucts were also explored for their potential antiviral activities [6, 21, 47]. For
example, ﬂavonoids were found to inhibit the NS2B/NS3 protease albeit weakly,
with IC50 values ranging from 15 to 44 mM [49]. Other group of compounds stud-
ied for their anti-dengue activities include novel thiadiazoloacrylamide analogues
with one of these showing moderate activity with IC50 values at 2.2 mM based on
NS2B/NS3 protease assay [56]. Meanwhile, two nitro derivatives of 3,5-
bis(arylidene)-4-piperidones were shown to inhibit NS2B/NS3 protease with
IC50 values of 15.22 and 16.23 mM [57]. However, most of these antiviral com-
pounds have only manifested moderate to weak anti-dengue activities. More eﬀorts
are certainly needed to discover novel inhibitors with signiﬁcant anti-dengue
activities.
AlphaScreen based assay is robust and has been widely utilized in various aspects
of cell signaling research, drug discovery and screening platform and biomarker
quantiﬁcation [58]. In this study, the NS2B/NS3 target peptide substrate was de-
signed and synthesized, whereby the substrate was tagged with a speciﬁc sequence
and polyhistidine, respectively. This strategy is favorably applicable to any enzymeon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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peptide substrate was adequately tagged at both N and C-terminals. Subsequently,
based on the cross-titration experiment and the typical bell-shaped curve, the opti-
mum concentrations of substrate and protease were determined at 300 nM and
100 nM, respectively. As for the optimization, several assay parameters were eval-
uated prior to the screening of derivatives. Lower concentrations of HEPES appeared
to produce higher signal intensity as compared to other types of buﬀer. Meanwhile,
concentrations of NaCl do not appear to aﬀect the signal much, therefore a lower
concentration of NaCl (20 mM) was used in this assay. In previous study, the opti-
mum activity of NS2B/NS3 protease was usually in the presence of low concentra-
tions of NaCl [22, 59]. Quite surprisingly 0.03e0.3% (w/v) BSA in the presence of
10 mM HEPES and 20 mM NaCl improved the signal tremendously. Yang and co-
workers have also used HEPES, NaCl and BSA for the assay solution in their
AlphaScreen assay [41]. Highest maximum signal within the range of 1.4 million
cps was obtained at pH 9.0, indicating improved sensitivity [59, 60]. This observa-
tion concurred with other studies which stated that the activity of NS2B/NS3
increased sharply from pH 7 to 9 [22, 59]. A 24 h incubation period produced signif-
icantly lower minimum signal which simply indicated that longer time was needed
for the peptide substrate to be completely cleaved by the protease. This may be due
to the reasonably low speciﬁc activity of NS2B/NS3 protease produced in the labo-
ratory and improving the speciﬁc activity may reduce the incubation period. The
ﬁnal optimum assay solution in this assay consisted of 10 mM HEPES, 20 mM
NaCl, 0.2% (w/v) BSA and at pH 9.
Subsequently known compounds such as aprotinin and a natural compound reported
to have some NS2B/NS3 protease inhibitory activities such as panduratin A was
evaluated using the optimized assay. Aprotinin, a broad spectrum protease inhibitor,
was found to inhibit dengue NS2B/NS3 protease with an IC50 value of 0.35 mM us-
ing AlphaScreen assay, which was rather similar with the value derived using the
protease assay. Interestingly, the published IC50 value of aprotinin was much lower
(65 nM) in a diﬀerent assay system on similar enzyme activity [59]. A diﬀerence in
speciﬁc activity for the expressed proteases and type of substrates used may have
contributed to this discrepancy. Surprisingly, panduratin A did not exhibit remark-
able activity against NS2B/NS3 enzyme, as an IC50 value of more than 100 mM
was expected based on the AlphaScreen assay. In fact, protease assay produced
an IC50 value of 211.5 mM when higher concentration range of the compound
was tested, a value higher than previously reported [57].
Appropriate and speciﬁc inhibitors that can be used as good controls in assays are
currently lacking for the NS2B/NS3 enzyme. Studies by Leung and co-workers
have found that even standard serine protease inhibitors such as 4-(2-aminoethyl)
benzenesulfonyl ﬂuoride.hydrochloride and N-Tosyl-L-phenylalanine chloro-
methyl ketone showed only 20e30% inhibition of this enzyme at 500 mM and 1on.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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was found included soybean trypsin inhibitor, 4-Amidinophenylmethanesulfonyl
ﬂuoride.hydrochloride, phenylmethylsulfonyl ﬂuoride, leupeptin, pepstatin A, ben-
zamidine and N-Tosyl-L-lysine chloromethyl ketone.hydrochloride [59]. On the
other hand, aprotinin is not a speciﬁc NS2B/NS3 inhibitor, thus may be an added
limitation for such assays. Both AlphaScreen and protease assays have indicated
that panduratin A activity on NS2B/NS3 protease was weak and thus, may not be
suitable to be used as positive control inhibitor for NS2B/NS3 protease. Tan and
co-workers initially determined the NS2B/NS3 inhibitory activities of hydroxypan-
duratin and panduratin A using protease assay and found that concentration as high
as 200 mM (or 80 ppm) was needed to inhibit 65-80% of the protease activity. Ki
values derived were 21 and 25 mM, respectively, indicating moderate to weak inhib-
itory eﬀects [21]. However, (8-HQ)-aminobenzothiazole derivatives with 2-
aminothiazole or 2-aminobenzothiazole scaﬀold synthesized by Lai and co-
workers, produced low IC50 values in the in vitro protease assays [61]. The most
potent 8-HQ-aminobenzothiazole inhibitor has an IC50 value of 0.91  0.05 mM
and Ki value of 2.36  0.13 mM [61]. This competitive inhibitor for DENV2
NS2B/NS3 protease may be useful as positive controls in assays targeting this
protease.
Unfortunately, none of the fourteen derivatives showed signiﬁcant inhibitory activ-
ity against dengue NS2B/NS3 protease despite earlier in silico simulation results
suggested otherwise. Only compound 4 was found to weakly inhibit the NS2B/
NS3 protease with an IC50 value probably near to 1 mM as determined using
both AlphaScreen and protease assays. Although the calculated FEB usually cor-
relates with the binding aﬃnity and that the lower energy obtained, the stronger the
binding aﬃnity and the more likelihood to exhibit inhibitory activity against the
protease, this was not observed in majority of the synthesized compounds.
Currently no DENV NS2B/NS3 protease inhibitors have advanced to clinical trials
despite numerous eﬀorts to ﬁnd potent inhibitors [15]. A main hurdle for such dif-
ﬁculty in designing small molecule inhibitors includes the nature of the NS2B/NS3
protease that has a shallow and hydrophilic catalytic site and that the active site
preferentially binds substrates with basic (positively charged) residues [62]. For
an inhibitor to bind, the substrate binding site requires a substantial conformational
change of the NS2B fragment, thus, designing inhibitors by structure-based design
has been challenging [63]. Hence, other strategies to identify inhibitors that bind to
other region of the protein to inhibit its function would probably to overcome the
hurdles.
Recently, a study has attempted to develop a conformational switch assay based on
split luciferase complementation to monitor conformational change of NS2B and to
identify candidate allosteric inhibitors [62]. In this assay, N- and C-terminal frag-
ments of luciferase are genetically fused to a protein pair of interest, and wouldon.2018.e01023
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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used to monitor the conformational changes of NS2B triggered upon binding of an
active site inhibitor to the NS2B/NS3 protease complex and was used to identify and
characterize allosteric inhibitors that prevent NS2B from forming the active confor-
mation [62]. And interestingly a compound was found inhibit the conformational
change of NS2B and signiﬁcantly reduce titers of DENV2 with low EC50 values,
although it was proved to be broad spectrum and not speciﬁc to NS2B/NS3 [62].
This is a ﬁrst report on the utilization of AlphaScreen beads for screening of dengue
NS2B/NS3 protease inhibitory activity. Although Takahashi and co-workers used
similar method to examine the interaction between NS3 and NS5, these interactions
could also serve as targets for the development of new antivirals against DENV [64].
As a conclusion, based on the zʹ factor, coeﬃcient variance and S/B ratios, this
AlphaScreen assay to screen for NS2B/NS3 protease inhibitors is potentially appli-
cable for use in high throughput screening [38, 41]. Further optimization in the
expression and puriﬁcation of NS2B/NS3 protease are needed to obtain higher activ-
ity and using newer speciﬁc inhibitors may improve the reliability of the assay.
Although a thioguanine derivative with a weak NS2B/NS3 protease inhibition activ-
ity was identiﬁed, this compound may be used as a starting compound for further
modiﬁcations and/or improvements. More comprehensive molecular simulation is
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